Custom Index Systems LLC increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 11.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,458 shares of the medical research company’s stock after acquiring an additional 356 shares during the quarter. Custom Index Systems LLC’s holdings in Quest Diagnostics were worth $473,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of DGX. Vanguard Group Inc. raised its stake in Quest Diagnostics by 2.5% during the first quarter. Vanguard Group Inc. now owns 13,921,955 shares of the medical research company’s stock valued at $1,853,151,000 after purchasing an additional 345,754 shares in the last quarter. Wellington Management Group LLP raised its stake in Quest Diagnostics by 0.7% during the fourth quarter. Wellington Management Group LLP now owns 2,632,326 shares of the medical research company’s stock valued at $362,945,000 after purchasing an additional 18,533 shares in the last quarter. Norges Bank purchased a new stake in Quest Diagnostics during the fourth quarter valued at $140,472,000. Nuance Investments LLC raised its stake in Quest Diagnostics by 13.1% during the first quarter. Nuance Investments LLC now owns 681,636 shares of the medical research company’s stock valued at $90,733,000 after purchasing an additional 79,152 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Quest Diagnostics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 663,917 shares of the medical research company’s stock valued at $91,541,000 after purchasing an additional 17,085 shares in the last quarter. Institutional investors own 88.06% of the company’s stock.
Insiders Place Their Bets
In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of the stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the transaction, the senior vice president now directly owns 5,019 shares in the company, valued at approximately $718,118.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Quest Diagnostics news, SVP Mark E. Delaney sold 420 shares of the stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the transaction, the senior vice president now directly owns 5,019 shares in the company, valued at approximately $718,118.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total transaction of $304,987.40. Following the transaction, the senior vice president now owns 11,459 shares in the company, valued at $1,756,206.34. The disclosure for this sale can be found here. 0.79% of the stock is owned by company insiders.
Analysts Set New Price Targets
Get Our Latest Stock Report on Quest Diagnostics
Quest Diagnostics Trading Down 0.8 %
DGX stock opened at $152.93 on Friday. The company has a market capitalization of $16.99 billion, a PE ratio of 20.58, a P/E/G ratio of 2.86 and a beta of 0.89. Quest Diagnostics Incorporated has a 12 month low of $119.59 and a 12 month high of $159.36. The firm’s 50-day moving average is $147.73 and its 200 day moving average is $138.97. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.00 and a quick ratio of 0.91.
Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.31 by $0.04. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm’s revenue was up 2.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.30 EPS. On average, research analysts anticipate that Quest Diagnostics Incorporated will post 8.89 EPS for the current year.
Quest Diagnostics Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, October 21st. Investors of record on Friday, October 4th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 1.96%. The ex-dividend date is Friday, October 4th. Quest Diagnostics’s dividend payout ratio is presently 40.38%.
Quest Diagnostics Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
See Also
- Five stocks we like better than Quest Diagnostics
- How to invest in marijuana stocks in 7 steps
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- Insider Buying Explained: What Investors Need to Know
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Upcoming IPO Stock Lockup Period, Explained
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.